This session looks at common risk issues associated with institutional review boards (IRB) and consent issues, the use of unapproved drugs/devices and how to coordinate IRB activities among hospital departments to minimize risk. The session also deals with education for IRB members and hospital staff, the financial risks associated with research and IRB activities and how to prepare for an FDA audit. Reporting requirements of research activities are covered, too.